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The concept of skin-associated lymphoid tissue embraces 
those cells and functions that are integrated in the cutaneous 
host defense. Recently, it has been possible to identify those 
circulating T -cells that are skin associated. These cells display 
the cell-surface phenotype of memory T cells (CD45RO+) 
and express the cutaneous lymphocyte antigen, a tissue-se-
lective homing receptor involved in directing T-cell traffic to 
inflamed skin. To investigate the participation of this skin-
associated T-cell subset in the pathogenesis of cutaneous T-
cell lymphoma, we studied 16 patients with erythrodermic 
cutaneous T -cell lymphoma for the presence of these surface 
proteins on circulating cells. Results were compared with 
eight patients in remission and eight with minimal patch-
plaque cutaneous T -cell lymphoma. The m ean expression of 
T he distribution of the immune repertoire and the funct ional coordination of spatially distinct compart-ments of the immune system is critically dependent on a closely regulated system oflymphocyte homing. This system directs naive T lymphocytes to the orga-
nized lymphoid microenvironment of secondary lymphoid tissues, 
such as lymph nodes or Peyer's patches, in which they can be specif-
ically ac tivated by thei r specific foreign antigen in conjunction with 
appropriate accessory cells. Naive T cells (CD45RA +RO- ) [1- 5] 
extravasate poorly, if at all, in extralymphoid ("tertiary") sites. In 
contrast, memory/effector T cells (CD45RO+) generated in sec-
ondary lymphoid tissues in response to stimulation by antigen mi-
grate efficiently to such sites, where they "patrol" for the return of 
their particular antigen. Memory/effector T cells do not, however, 
home equivalently to all possible tissues; instead they demonstrate 
tissue-selective homing to particular secondary and tertiary sites 
(reviewed in [1 D. 
One such site receiving a distinct subset of memory T cells in 
response to inflammatory stimuli is the skin. Recent studies indicate 
that T-cell extravasation at cutaneous sites of chronic inflammation 
is dependent on the interaction of the cutaneous lymphocyte-asso-
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both CD45RO and cutaneous lymphocyte antigen were sig-
nificantly greater in the erythrodermic patients than in the 
other two patient groups. Expression of these markers was 
shown to be on the cells of the m alignant clone by two-color 
flow cytometry. These results demonstrate that the malig-
nant cells of cutaneous T -cell lymphoma express the markers 
of skin homing lymphocytes and that their levels are in-
creased in the erythrodermic cutaneous T-cell lymphoma 
patients. Moreover, the findings suggest a critical role for the 
skin-selective homing receptor cutaneous lymphocyte anti-
gen in the pathogenesis of cutaneous T -cell lymphoma. Key 
words: cutaneous T-cell lymphoma, cutaneous lymphocyte 
antigen, CD45 isoforms. ] itlllest D ermatol 101 :222 - 226, 
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ciated antigen (CLA) with endothelial cell E-selectin (formerly 
known as ELAM-l) , which in the setting of chronic inflammation 
is preferentially induced on cutaneous venul es (i.e. , is a skin vascular 
"addressin") [6 - 9]. CLA is expressed on the vast majority ofT cells 
within cutaneous inflammation si tes, and on a subset of peripheral 
blood memory cells, but not on the great majority of T cells in 
extracutaneous sites [6,7]. Cutaneous T -cell lymphoma (CTCL) is a 
disease characterized by cutaneous infiltrates of ma lignant c10nally 
expanded T cells admixed with an inflammatory infi ltrate. The 
disease typically begins with erythematous patches, which then 
progress to more infiltrated plaques [10] . Dissemination of CTCL 
cells can occur hematogenously. When this occurs, the clinical 
picture of erythroderma may appear. The malignant cells in CTCL 
are a c10nally expanded T-cell subpopulation that contain the same 
T-cell receptor (TCR) gene rearrangements [11]. 
Recombination of genes encoding the variable regions of the 
chain of the T-cell receptor (TCR) contribute greatly to the genera-
tion of diversity in the TCR [1 2]. The number of different variable 
regions for the human chain is probably greater than 40 but the 
precise number is not known [13]. Monoclonal antibodies with 
specificity for a small number of these are already available, defilLing 
fami lies of TCRs (as shown in T able I) . No single one of these 
identifiable variable regions is expressed on more than 5% of circu-
lating T cells in normal individuals , and most are expressed on less 
than 3%. The validity of the use of a particular family-specific 
antibody to identify the malignant clone was confirmed by us in an 
RNAse protection assay, demonstrating CTCL cell production of 
message for these same variable regions [13]. Thus, it is possible to 
clearly identify malignant cells in select patients with antibodies 
directed against the variable region sequences for the beta chain 
[14]. 
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Table I. Monoclonal Antibodies for Variable Regions 
of the Human Chain 
Name 
VB5(a) 
VBS(b) 
VB5(c) 
VB6(a) 
VB8(a) 
VB12(a) 
Immunogen 
Normal donor PBL 
Normal donor PBL 
SUP-T13 T-cell line 
T-CLL PBL 
Jurkat T-cell line 
Sezary PBL 
Specificity 
VBS.2 + VBS.3 
VBS.3 
VBS.l 
VB6.7 
VB8 
VB12.1 
CLA has been demonstrated to be present on the surface of skin-
infiltrating lymphocytes in all patients studied with patch-plaque 
CTCL, but not non-skin-associated T-cell lymphomas [6J, sug-
gesting the possibility that the CLA:E-selectin interaction plays a 
role in the epidermotropic nature of this unique neoplasm. To in-
vestigate this hypothesis, we sought to quantify T cells of the skin 
homing phenotype in the peripheral blood of patients with erythro-
dermic CTCL, patients with minimal patch/plaque CTCL, and 
patients with CTCL in remission. Our results indicated that pa-
tients with erythrodermic CTCL have increased circulating lym-
phocytes bearing both CLA and CD45RO. Two of the patients in 
this study had malignant clones detectable by one of the panel of 
variable region antibodies. In those patients it can be clearly demon-
strated that the circulating CLA + and CD45RO+ cell s were malig-
nant cells on th e basis of co-expression with the family-specific 
antibody. 
MATERIALS AND METHODS 
Patients A total of 16 patients with erythrodermic CTCL were evaluated 
in conjunction with their visits to the Dermatology Clinic at Yale Univer-
sity. All had a skin biopsy diagnostic of CTCL (morphologically atypical 
cells in dermal infil trates and in the epidermis, with Pautrier abscess forma-
tion) in conjunction with erythroderma. Eight patients with patch-plaque 
disease « 10% body surface area) of CTCL were studied, as were eight 
patients in remission from erythrodermic CTCL at the time of study. 
Preparation of Peripheral Blood Mononuclear Cells Patients' blood 
samples were collected in tubes containing heparin. Peripheral blood mono-
nuclear cells (PBMC) were isolated by density gradient centrifugation as 
follows. Whole blood was diluted with Hank's balanced salt solution 
(HBSS) (GIBCO) ata ratio of3: 1. The diluted blood was layered over Ficoll 
Histopaque-l077 (Sigma Diagnostics) and centrifuged at 300 X g for 
35 min at room temperature. The PBMC were harvested from the interface, 
resuspended, and washed two times in HBSS with 5% fetal calf serum 
(GIBCO). 
Monoclonal Antibodies Patients' PBMC were incubated with a variety 
of monoclonal antibodies. The anti-CD4SRO (UCHLl) was directly con-
jugated with fluorescein isothiocynate (FITC) (Dakopatts, Denmark). The 
unconjugated murine monoclonal antibodies listed in Table I were pur-
chased from T-cell Sciences, Cambridge. The antibody to CLA was directly 
conjugated with FITC and this was prepared as previously described [6,7J. 
Mouse ascites fluid was prepared and utilized as previously described [1 5] to 
control for non-specific binding of murine antibody in both one-color and 
two-color stndies. The secondary antibody, FITC-conjugated goat anti -
mouse IgG, was purchased from The Binding Site, San Diego. 
Immunofluorescence Isolated PBMC were incubated with primary 
monoclonal antibody at a concentration of 100,000/10 J.Ll cells for 30 min at 
4 ° C. The primary monoclonal antibodies were used at concentrations of 0.2 
Ilg/I0 Ill. After the incubation period, the cel ls were resuspended and 
washed two times by centrifugation at 200 X g (4 °C) for 5 min with 500 pI 
PBS (pH 7.4) containing 10% human serum, type AB (GJBCO) and 0.1 % 
sodium azide. FITC-conjugated goat anti-mouse was added to the cells at a 
concentration of 5 Ilg/I0 III with 10 pl/l00,OOO cells used in incubation for 
30 min at 4°C. After the secolJdary staining, the PBMC were washed as 
stated above. 
For two-color immunofluorescent studies, isolated PMBL were initially 
stained with a monoclonal antibody to the T-cell receptor variable region 
(either VBS[a] or VB8[a]), which was diluted as described above. The cells 
were incubated, washed, and resuspended as described in the previous sec-
tion. The secondary antibody, biotinylated goat anti-mouse IgG, was pur-
chased from Vector Laboratories and the stock solution was diluted 1: 200 
with PBS. After incubation with the biotinylated antibody, the cells were 
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resuspended and washed two times by centrifugation at 200 X g (4 °C) for 
5 min with 500 Ill/PBS (pH 7.4) containing 10% human serum, type AB 
(GIBCO) and 0.1 % sodium azide. Following the last washing step, the cells 
were stained with phycoerythrin-conjugated avidin (PE-A) (CALTAG, 
Laboratories), which was diluted with PBS to a concentration of 1: 10. After 
a 3D-min incubation, ce lls were washed twice as described above and then 
incubated with the FITC-co~ugated monoclonal antibody to CD45RO or 
CLA. 
Flow Cytometry Analysis For flow cytometry analysis, the cells were 
resuspended in a final volume of 500 III PBS. A cytofluorograph IIa (Ortho 
Diagnostics Systems Inc, Westwood, MA) with an Argon laser (Exel , West-
wood, MA) was used for fluorescence analysis. Gating was performed on 
lymphocytes and background fluorescence was set at 5%. The percentages of 
positive ce lls were obtained by subtracting 5% from the percent expressing 
cells. For two-color flow cytometry, red and green background fluorescence 
was set at 5%. The two-color flow cytograms were divided into four quad-
rants based on each line being drawn at 5% control immunofluorescence. 
The percentage of cells in each quadrant is displayed on the cytogram. 
Results were thus expressed as a percentage of total lymphocytes. Two-
color flow cytometry was performed on a Dual Laser FACS IV (Becton 
Dickinson). 
Statistical Analysis The correlation coefficient (r) was used to measure 
the strength of the linear association between the flow cytometric results 
with CD4SRO and CLA. Student t test was used to test for differences 
between the study groups: p < 0.05 was considered significant. 
RESULTS 
CD45RO Expression The results of memory cell analysis on 
PBMCs from CTCL patients in remission and those w ith limited 
cutaneous disease were similar to those reported for normal controls 
[4] . In the 16 non-leukemic patients, CD45RO was expressed on a 
mean of 15% of total lymphocytes in the eight in remission, and a 
mean of 13.5% of total lymphocytes in the eight patients with 
patch-plaque disease. None of the patients in remission or with 
limited patch-plaque disease had greater than 33% of peripheral 
blood lymphocytes expressing CD45RO, whereas most of the leu-
kemic patients were above this level, as shown in Fig 1. 
In the leukemic CTCL group CD45RO expression was mark-
edly elevated, with a mean of 56% of total lymphocytes, which was 
significantly higher than that seen in the non-leukemic patients 
(p < 0.05) . 
Coexpression of CD45RO and TCR VB Epitopes Of all 16 
leukemic patients screened with the panel of the variable region of 
the beta chain of the T-cell receptor (VB) antibodies in Table I, only 
two patients were identified with elevated levels of circulating cells 
expressing a particu lar VB. Normally , less than 5% of circulating 
cells express a given VB. One patient had circulating cells express-
ing 77% VB8; 4 weeks later this patient had 84% VB8(a) expressing 
cells. The second patIent had 93% VB5(a) expressing cells. Two-
color flow cytometry demonstrated that CD45RO is expressed on 
the malignant clone. In Fig 2, the percentage of CD45RO+VB8+ 
cells in that patient was 67% whereas only 4% were 
CD45RO+VB8- and 11 % were CD45RO- VB8+. 
CLA Expression The results of CLA expression ana lys is o n 
PBMCs from CTCL patients in remission and those with limited 
cutaneous disease were similar to those reported for normal controls 
[6]. The percentage of lymphocytes bearing CLA in the 16 non-leu-
kemic patients showed a mean of 15.5 for the eight in remission, 
and a mean of 14.5 for the eight patients with patch-plaque disease. 
None of the limited patch-plaque disease patients or those in remis-
sion had greater than 21 % of peripheral blood lymphocytes ex-
pressing CLA, as shown in Fig 3. In contrast, in the leukemic CTCL 
group, CLA expression was significantly elevated, being expressed 
on a mean of 52% of peripheral blood lymphocytes (p < 0.01 com-
pared to non-leukemic patients). In addition, 14 of the 16 patients 
had > 21 % of peripheral blood lymphocytes expressing CLA. 
Coexpression of CLA and TCR VB Epitopes In the results 
presented above it was reported that VB antibody screening of pe-
ripheral blood lymphocytes found that one patient's peripheral 
blood lymphocytes expressed the epitope recognized by VB5(a) and 
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Figure 1. CD45RO expression on total peripheral lymphocytes in CTCL 
patients. On the left (A) are eight patients in remission from CTCL (mean 
15%). In the wlter (B) are eight patients with patch-plaque disease « 10% 
body surface area) with a mean of 13.5%. The 16 leukemic patients (C) on 
the right had a mean of 56% (p < 0.05 versus the other two groups). 
one recognized by VB8(a). Two-color flow cytometry with the VB 
antibodies demonstrated that CLA is expressed on the malignant 
clone (Fig 4A,B). The patient sample shown in Fig 4A was the same 
patient as in Fig 2 at a later date, when 84% of the peripheral blood 
lymphocytes were expressing VB8. In Fig 4A, 52% of the circulat-
ing lymphocytes were CLA+VB8+; however, 32% of the lympho-
cytes expressed VB8 but did not express CLA. The patient sample in 
Fig 4B was characterized by having 93% of the lymphocytes ex-
pressing the VB epitope recognized by antibody VB5(a). As shown 
in Fig 4B, a large number of clonally expanded VB5(a)+ cells are 
CLA + (52%). As with the patient sample in Fig 4A, there were VB+ 
and CLA - peripheral blood lymphocytes (41 %). 
Correlation of CD45RO and CLA In Fig 5, each patient ana-
lyzed is represented by a single point whose position was plotted as a 
dual function of the percentage of CD45RO+ lymphocytes (y-axis) 
and the percentage of CLA + lymphocytes (x-axis). As can be seen in 
Fig 5, each patient is represented by a single point. There was a 
positive correlation between CLA and CD45RO expression with a 
correlation coefficient r = 0.70 (p < 0.05). 
DISCUSSION 
The concept that the skin constitutes a specific immunologic mi-
croenvironment is not a new one [16,17], but has received a great 
deal of support in recent years from studies indicating that unique 
constituents of the skin such as Langerhan's cells, keratinocytes, and 
melanocytes can extensively interact with lymphocytes, either by 
secretion of immunoreactive cytokines or by expression of cell ad-
hesion/recognition receptors (e.g., ICAM-1, HLA-DR) that medi-
ate direct cell-cell contact [18]. Moreover, it is now clear that the 
lymphocytes entering the skin are themselves a unique subpopula-
tion, and that the skin represents a distinct lymphocyte homing 
specificity [6,7]. Skin-associated lymphocytes are primarily T cells 
that display the CD45RO+ phenotype of memory T cells [19], and 
selectively express the cell-surface determinant CLA [6]. CLA is an 
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Figure 2. A two-color flow cytogram showing CD45RO expression (x-
axis) and TCR beta chain variable-region 8 (VB8a) expression (y-axis). The 
lines dividing the plot into quadrants intersect an axis at the fluorescence 
channel where < 5% of cells had greater fluorescence with control staining. 
The percentage of cells in each quadrant is displayed. 
oligosaccharide ligand for E-selectin, a vascular adhesion molecule 
that in the setting of chronic inflammation is preferentially ex-
pressed in skin, and it is thought that the CLA: E-selectin interac-
tion is a major determinant of the skin-selective T-cell homing 
specificity [1 ,6-9]. 
The clinical syndromes made up of certain T ce ll malignancies 
localizing to the skin have been collectively known as CTCL 
[10,20,21]. The existence of these skin homing lymphomas has 
long been used as an argument for a skin-selective homing specific-
ity in man. Now, with the recognition that there is a physiologic, 
skin-associated T-cell subset, it has become possible to address this 
issue from the reverse perspective, that of defining the cellular and 
molecular mechanisms underlying the distinct pathophysiology of 
these neoplasms. In this report, we demonstrate that patients with 
erythrodermic CTCL have in their peripheral blood elevated levels 
of cells expressing the memory marker CD45RO and the skin 
homing receptor CLA. Moreover, in patients whose malignant 
clone could be unequivocally identified with monoclonal antibod-
ies against T-cell receptor variable region'epitopes, the predominant 
phenotype of the malignant population was CD45RO+, CLA+. 
These results are in keeping with a previous study demonstrating 
the CTCL leukemic cells preferentially home to skin [22]. and are 
consistent with studies showing that the malignant skin infiltrates 
of patch/plaque-stage mycosis fungoides have a memory T-cell 
phenotype [23], and are predominantly CLA+ [6] . As CLA expres-
sion is not a feature ofT-cell lymphomas in extracutaneous sites [6], 
these observations suggest that the variants of CTCL that have 
appeared under the colorful names of mycosis fungoides, Pagetoid 
reticulosis, Sezary syndrome, etc. can now be unified by the concept 
that they are malignancies of cutaneous T cells (skin homing mem-
ory T cells). The studies of CLA expression also suggest that the 
same mechanisms directing the normal skin-selective homing of 
this subset may underlie the distinctive skin localization of these 
neoplasms. 
Recent advances in the understanding of the normal regulation of 
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Figure 3. CLA expression on total peripheral blood lymphocytes in CTCL 
patients. On the lr:Jt (A) are eight patients in remission from CTCL (mean 
15.5%). In the (elller (B) are eight patients with patch-plaque disease « 10% 
body surface area) with a mean of 14.5%. The 16 leukemic patients (C) on 
the right had a mean of 52% CLA+ cells (p < 0.05 versus the other two 
groups). 
CD45 isoforms and CLA in physiologic situations suggest provoca-
tive hypotheses on the origins and pathogenesis of CTCL. Virgin T 
cells emigrating from the thymus or recirculating among secondary 
lymphoid tissues have a CD45RA+/CLA- phenotype. Activation 
of these virgin T cells in secondary lymphoid tissues leads to the 
replacement of CD45RA by the RO isoform, and, depending on the 
local microenvironment, upregulation of CLA (CLA upregulation 
is over five times more frequent in peripheral lymph nodes draining 
skin than in non- skin-associated secondary lymphoid tissues such 
as the appendix [24,25)). Cutaneous T cells obtained from suction 
blisters overlying delayed hypersensitivity reactions are almost en-
tirely CD45RO+ [19]' and CLA + (the mean CLA expression of 
cutaneous T cells is 23 times higher than that of peripheral blood T 
cells [25]. Because malignant transformation likely occurs or be-
comes manifest in a proliferating cell, the finding that CTCL cells 
are CD45RO+/CLA+ suggests that malignant T-cell clones of 
CTCL arise either in T cells undergoing the virgin-to-memory 
transition in secondary lymphoid tissues (most likely peripheral 
lymph node) or in CLA+ memory T cells activated in the skin. 
Thus, it is likely that at the time of transformation, CTCL clones 
have "seen" antigen and undergone antigen-driven activation [26] . 
The microenvironment of this activation is presumably favorable to 
the upregulation of the CLA epitope. Furthermore, it is possible 
that the maintenance of CLA expression on the malignant clone 
requires continued re-stimulation in an appropriate microenviron-
ment. The finding that CTCL cells often express a T-cell receptor-
mediated activation marker (BE2) is in keeping with this hypothesis 
[15,27]. 
A requirement for continuous CLA upregulation might explain 
the finding that not all circulating CTCL cells are CLA + (Fig 4). 
The CLA+ and CLA- subsets might reflect cells recently exposed to 
the cutaneous or other appropriate microenvironment versus those 
not receiving such CLA-inducing signals. Another explanation for 
the VB+CLA - cells would be that these are tumor cell s in the pro-
cess of dedifferentiation . Followup studies will determine if this is a 
sign of tumor progression. 
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Figure 4. (A) Two-color flow cytograms from two CTCL patients show-
ing CLA expression on the x-axis and TCR VB expression on the y-axis 
[VB8(a) for the patient 111 A, VB5(a) for the patient in B]. The lines dividing 
the plots into quadrants intersect an axis at the fluorescence channel where 
< 5% of cells had greater fluorescence with control staining. The percent-
ages of cells in each quadrant are listed in the quadrant. 
Clinical progression of CTCL is associated with loss of epider-
motropism and widespread dissemination [10]. It is possible that loss 
of CLA expression with tumor dedifferentiation plays a role in this 
process. Such loss may occur directly, with loss of expression of the 
core polypeptide of CLA or the glycosyl transferases required to 
produce its unique oligosaccharide side chain, or may occur indi-
rectly by virtue of the tumor losing the ability to respond to CLA-
inducing stimuli. Preliminary observations suggesting that devel-
opment of (non-epidermotropic) tumor stage CTCL is associated 
with (and perhaps preceeded by) loss of CLA expression [6] support 
this hypothesis. 
Previous studies have suggested the potential utility of T-cell 
receptor variable region-specific antibodies in the diagnosis and 
monitoring of T-cell malignancies [14] ; the results of this study 
confirm this potential. Unfortunately, the current paucity of rea-
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Figure 5. The correlation of CD45RO express ion with CLA expression in 
CTCL patients. All patients in this study were plotted as a point determined 
by their CLA expression (x-axis) and CD45RO express ion (y-axis) to dem-
onstrate the positive correlation (r = 0.70, P < 0.001). 
gents prevents application of this technique to all patients with 
CTCL. As the avail able panel of such reagents becomes more com-
plete, or in those patients whose malignant cells happen to bind one 
of the currently avail able reagents, the use of multiparameter fl ow 
cytometry to simultaneously assess the expression of the clone-spe-
cific T-cell receptor variable regions, CLA and CD45RO, will pro-
vide new insights into the pathophysiology of lymphomas of cuta-
neous T cells. 
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